Back to the main directory
EarningsReview / Equity
- Orkla (Buy, TP: NOK105.00) - Strong figures from Jotun by DnB Markets
- The Kingfish Company (No_rec, TP: NOK) - Recommendation and target price withdrawn by DnB Markets
- OPEC cuts unlikely to stop jack-up additions by DnB Markets
- Decline continues by DnB Markets
- Weathering the storm by BNP Paribas Exane
- Thoughts Into CQ4 by BNP Paribas Exane
- Memory Monthly: Making sense of capacity plans, export controls, and pricing by BNP Paribas Exane
- At a tipping point by BNP Paribas Exane
- Total Recall by BNP Paribas Exane
- Sustainability Weekly 3 – 7 October 2022 by Oddo BHF
- The eye of the storm by BNP Paribas Exane
- DEUTSCHE POST: RDOS. PRELIMINARES 3T’22 (ANÁLISIS BANCO SABADELL) by Sabadell
- Turbulence Ahead by BNP Paribas Exane
- Electric Shock: Battery Battles by BNP Paribas Exane
- TCS (TCS IN) by HSBC
- Genmab - Managing expectations into ASH by Danske Bank Equity Research
- Skanska (Buy, TP: SEK210.00) - Balance-sheet strength key by DnB Markets
- Boliden (Buy, TP: SEK470.00) - On course for impressive earnings by DnB Markets
- Swedish Orphan Biovitrum (Buy, TP: SEK265.00) - Set for another strong quarter by DnB Markets
- Top picks: cash-rich and diversified by DnB Markets
- Kazia Therapeutics - PNOC022 trial expanded by Edison Investment Research
- Not what it once was by BNP Paribas Exane
- Box recession, but derated valuations with catalysts by BNP Paribas Exane
- INVEST SECURITIES - MEDESIS : Fin de partie COVID, le cerveau passe en 1ère ligne - ACHAT, OC 7,5€ (vs 11€) by Invest Securities
- 中国绿色氢能行业 by HSBC